Avinger (NASDAQ:AVGR) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a research report released on Wednesday. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of Avinger in a research report on Thursday, March 21st.

Avinger Price Performance

Shares of AVGR opened at $3.73 on Wednesday. The company has a market cap of $5.93 million, a P/E ratio of -0.14 and a beta of 1.26. The stock has a fifty day moving average price of $3.47 and a 200 day moving average price of $3.34. Avinger has a 12 month low of $2.50 and a 12 month high of $18.00.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.52 million. As a group, research analysts anticipate that Avinger will post -2.08 earnings per share for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.